Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

The deal with the U.K.’s Nuclear Decommissioning Authority runs for 15 years with an option to renew for a “potentially ...

Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...